Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Jan 14, 2020
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Oct 09, 2019
AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress
May 28, 2019
SKYRIZI(TM) (risankizumab-rzaa) Now Available From BioPlus Specialty Pharmacy for Moderate to Severe Plaque Psoriasis
Apr 30, 2019
European Commission Approves SKYRIZI(TM) (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Apr 23, 2019
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI(TM) (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Apr 18, 2019
Health Canada Approves SKYRIZI(TM) (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Mar 26, 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Mar 07, 2019
Novel antibody shows potential to transform treatment of rare form of psoriasis
Mar 01, 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Sep 13, 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
May 01, 2018
AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Apr 25, 2018
AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Mar 05, 2018
Global Psoriasis Pipeline Drugs Market 2018-2023: Cimzia (Certolizumab Pegol), Tildrakizumab (MK-3222), Risankizumab (BI 655066), FP187, Skilarence (LAS41008) & Duobrii (IDB 118)
Feb 19, 2018
AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Feb 17, 2018
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
Feb 12, 2018
AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting
Jan 15, 2018
Global Immunology Market 2018-2022: 51 Molecules - 22 Molecules in Phase II, 4 Molecules in Phase III, 16 Molecules in Phase I, and 9 in Phase I/Il Clinical Trials
Dec 04, 2017
Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study